The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.
From wheat fields to Washington: a decades-old fear about skies and 'sprays' rises again, colliding with science, social media, and the machinery of federal policymaking.